Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0005953,
umls-concept:C0007634,
umls-concept:C0036576,
umls-concept:C0038250,
umls-concept:C0039194,
umls-concept:C0205160,
umls-concept:C0205173,
umls-concept:C0332283,
umls-concept:C0333668,
umls-concept:C0667141,
umls-concept:C0882849,
umls-concept:C1280500,
umls-concept:C1446409,
umls-concept:C1705294,
umls-concept:C2004454
|
pubmed:issue |
2
|
pubmed:dateCreated |
1998-11-17
|
pubmed:abstractText |
An advantage of CD34+ cell selection over antibody purging is that a component allograft is produced comprising a stem cell enriched and an unadsorbed fraction, the latter containing T cells which may be used for post-transplant immunotherapy. Initial reports with PBSC allografts suggested that T cell depletion (TCD) by CD34+ cell selection and post-graft cyclosporin A +/- methotrexate was insufficient prophylaxis against acute GVHD. We compared sequential TCD (of a CD34+ cell-selected fraction) using a second (CD2) immunoaffinity step or Campath-1M monoclonal antibody and complement. Since a high stem cell 'dose' enhances engraftment across HLA barriers and improves overall post-transplant outcome, the recovery of CD34+ cells and progenitors were assessed. Sequential positive (CD34+) and negative (CD2+) immunoaffinity selection resulted in a 3.4 log depletion of T cells as compared to a 4.05 log depletion when CD34+ cell selection was followed by Campath-1M treatment. Recoveries of CD34+ cells, CFU-GM and BFU-E following double depletion using CD34+ cell selection plus CD2+ cell depletion were 28, 25 and 17% as compared to 20, 18 and 16% when CD34+ cells were treated with Campath-1M. The unadsorbed fraction contained 85% of the original T cells, from which donor leukocyte infusions in the range of 10(5) to 10(7) CD3+ cells per kg body weight of the recipient were harvested. Despite the advantages of component allografts, the loss of stem/progenitor cells may restrict sequential TCD steps unless single BM harvests are supplemented and/or replaced with mobilised PBSCs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0268-3369
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
117-24
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9707017-Antibodies, Monoclonal,
pubmed-meshheading:9707017-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:9707017-Antibodies, Neoplasm,
pubmed-meshheading:9707017-Antigens, CD34,
pubmed-meshheading:9707017-Bone Marrow Purging,
pubmed-meshheading:9707017-Bone Marrow Transplantation,
pubmed-meshheading:9707017-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:9707017-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9707017-Humans,
pubmed-meshheading:9707017-Immunosorbent Techniques,
pubmed-meshheading:9707017-Lymphocyte Depletion,
pubmed-meshheading:9707017-T-Lymphocytes,
pubmed-meshheading:9707017-Transplantation, Autologous,
pubmed-meshheading:9707017-Transplantation, Homologous
|
pubmed:year |
1998
|
pubmed:articleTitle |
Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.
|
pubmed:affiliation |
Bristol Institute for Transfusion Sciences, National Blood Service - Bristol Centre, UK.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|